JP2017531613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531613A5 JP2017531613A5 JP2017500335A JP2017500335A JP2017531613A5 JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5 JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- subject
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims description 28
- 101000924544 Homo sapiens Angiopoietin-like protein 8 Proteins 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 238000008214 LDL Cholesterol Methods 0.000 claims description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000003532 hypothyroidism Diseases 0.000 claims description 5
- 230000002989 hypothyroidism Effects 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059682P | 2014-10-03 | 2014-10-03 | |
| US62/059,682 | 2014-10-03 | ||
| PCT/US2015/053700 WO2016054494A1 (en) | 2014-10-03 | 2015-10-02 | Methods and compositions for treatment of conditions associated with elevated triglycerides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531613A JP2017531613A (ja) | 2017-10-26 |
| JP2017531613A5 true JP2017531613A5 (enExample) | 2018-11-08 |
| JP6680758B2 JP6680758B2 (ja) | 2020-04-15 |
Family
ID=55631597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500335A Expired - Fee Related JP6680758B2 (ja) | 2014-10-03 | 2015-10-02 | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10071139B2 (enExample) |
| EP (2) | EP3822287A1 (enExample) |
| JP (1) | JP6680758B2 (enExample) |
| AU (1) | AU2015327900B2 (enExample) |
| CA (1) | CA2954082A1 (enExample) |
| ES (1) | ES2819866T3 (enExample) |
| WO (1) | WO2016054494A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015327900B2 (en) | 2014-10-03 | 2020-04-30 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| JP6843872B2 (ja) * | 2016-02-04 | 2021-03-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 操作されたａｎｇｐｔｌ８遺伝子を有する非ヒト動物 |
| WO2017151783A1 (en) | 2016-03-03 | 2017-09-08 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
| CA3019635A1 (en) * | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| HUE056878T2 (hu) * | 2016-04-08 | 2022-03-28 | Regeneron Pharma | Hiperlipidémia kezelési módszerei ANGPTL8 inhibitorral és ANGPTL3 inhibitorral |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| US10774139B2 (en) | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| CA2838824A1 (en) * | 2011-06-10 | 2012-12-13 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
| ES2764833T3 (es) | 2013-10-11 | 2020-06-04 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Anticuerpos contra TEM8 y su uso |
| AU2015327900B2 (en) | 2014-10-03 | 2020-04-30 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| US10774139B2 (en) | 2017-11-10 | 2020-09-15 | Ngm Biopharmaceuticals, Inc. | ANGPTL8-binding agents and methods of use thereof |
-
2015
- 2015-10-02 AU AU2015327900A patent/AU2015327900B2/en not_active Ceased
- 2015-10-02 CA CA2954082A patent/CA2954082A1/en active Pending
- 2015-10-02 US US15/318,937 patent/US10071139B2/en active Active
- 2015-10-02 WO PCT/US2015/053700 patent/WO2016054494A1/en not_active Ceased
- 2015-10-02 JP JP2017500335A patent/JP6680758B2/ja not_active Expired - Fee Related
- 2015-10-02 ES ES15848061T patent/ES2819866T3/es active Active
- 2015-10-02 EP EP20185093.0A patent/EP3822287A1/en not_active Withdrawn
- 2015-10-02 EP EP15848061.6A patent/EP3201225B1/en active Active
-
2018
- 2018-08-06 US US16/056,068 patent/US10702587B2/en not_active Expired - Fee Related
-
2020
- 2020-05-29 US US16/888,249 patent/US20210015902A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531613A5 (enExample) | ||
| JP7474729B2 (ja) | 肺高血圧症を治療するための組成物および方法 | |
| JP7365715B2 (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| JP2014526441A5 (enExample) | ||
| Chrysant et al. | Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors | |
| JP2019178132A5 (enExample) | ||
| US10702587B2 (en) | Angiopoietin-like protein 8 polypeptide fragments and compositions thereof | |
| US10493135B2 (en) | Methods of treating tissue calcification | |
| JP2010513506A5 (enExample) | ||
| JP2012509902A5 (enExample) | ||
| AU2020340618B2 (en) | Therapeutic fusion proteins | |
| JP2009510999A (ja) | キメラ治療剤 | |
| Sarzani et al. | Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities | |
| JP2014519514A5 (enExample) | ||
| WO2013103972A1 (en) | Treatment of frailty syndrome and symptoms thereof | |
| CN105079780A (zh) | 一种特异结合trb3的多肽在治疗或预防腹主动脉瘤中的应用 | |
| JP2017509602A5 (enExample) | ||
| Moreno-Pérez et al. | Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney | |
| US20230357339A1 (en) | Development of Cell-Permeable Truncated SOCS3 SH2 Domain (CP-SD) Recombinant Protein for Anti-Obesity Agent | |
| Wagner et al. | Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial | |
| JP2018500386A5 (enExample) |